Is It Safe to Stop? Predictors and Outcomes of Treatment Discontinuation in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Authors:
- Haneen SabetHSHaneen Sabet
- Moaz Elsayed AbouelmagdMAMoaz Elsayed Abouelmagd
- Mark MessakMMMark Messak
- Mohamed Ahmed ZanatyMZMohamed Ahmed Zanaty
- Dalia Kamal EwisDEDalia Kamal Ewis
- Hamdy A. MakhloufHMHamdy A. Makhlouf
- Obai YousefOYObai Yousef
- Abdullah AlmarfadiAAAbdullah Almarfadi
- Omar ShakerOSOmar Shaker
- Abdelrahman ShataASAbdelrahman Shata
- Gergis AltalabGAGergis Altalab
- Omar KassarOKOmar Kassar
- 11 November 2026
- journal article
- review article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
Abstract
No abstract availableThis publication has 60 references indexed in Scilit:
- Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisJAMA Neurology, 2025
- High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MSJAMA Neurology, 2024
- Management of multiple sclerosis in older adults: review of current evidence and future perspectivesJournal of Neurology, 2024
- Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosisJournal of Neurology, 2022
- Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionJournal of Neurology, 2022
- Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological PerspectivesNeurotherapeutics, 2021
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Cochrane Handbook for Systematic Reviews of Interventions2019
- Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugsNeurological Sciences, 2017
- Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patientsJournal of Neurology, 2016